Biomarkers for prediction and diagnostics of preeclampsia
Preeclampsia (PE) is a life-threatening complication of pregnancy associated with a high rate of maternal and perinatal morbidity and/or mortality. This study was aimed at evaluation of total and fetal cell-free DNA (cftDNA and cffDNA) in maternal plasma to assess whether this could represent a reli...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Scientific Сentre for Family Health and Human Reproduction Problems
2018-04-01
|
| Series: | Acta Biomedica Scientifica |
| Subjects: | |
| Online Access: | https://www.actabiomedica.ru/jour/article/view/553 |
| _version_ | 1826853335015096320 |
|---|---|
| author | O. V. Radkov L. N. Korichkina O. V. Sizova Y. V. Volf E. K. Paramonova |
| author_facet | O. V. Radkov L. N. Korichkina O. V. Sizova Y. V. Volf E. K. Paramonova |
| author_sort | O. V. Radkov |
| collection | DOAJ |
| description | Preeclampsia (PE) is a life-threatening complication of pregnancy associated with a high rate of maternal and perinatal morbidity and/or mortality. This study was aimed at evaluation of total and fetal cell-free DNA (cftDNA and cffDNA) in maternal plasma to assess whether this could represent a reliable predictive marker of early, late PE and whether intrauterine growth restriction (IUGR) as seen in PE is associated with levels of cell-free DNA. Diagnostic criteria for fetal growth retardation are calculated from the results of blood test results obtained in 26-36 weeks of gestation. We performed a PCR assay to compare the cftDNA and cffDNA concentration in maternal plasma among 3 groups of pregnant women. These included 119 women with overt PE (47 - early PE, 72 - late PE), 24 women at risk for the disease who developed PE (8 -early PE, 16 - late PE), and 30 controls. CffDNA quantification is a promising marker for early preeclampsia prediction. Cut-off value of 0,87 ng/ml for cffDNA (87.5 % sensitivity and 66,67 % specificity). Since the increase in cftDNA and cffDNA seems to be related to the presence IUGR in pregnancies which are complicated with early PE. Thus, it suggests that cftDNA and cffDNA could represent a potential biomarker of IUGR among individuals with early PE. |
| first_indexed | 2024-03-08T12:17:56Z |
| format | Article |
| id | doaj.art-5a1b9dc062e24b2d9a6afb14cd15383c |
| institution | Directory Open Access Journal |
| issn | 2541-9420 2587-9596 |
| language | Russian |
| last_indexed | 2025-02-16T17:24:47Z |
| publishDate | 2018-04-01 |
| publisher | Scientific Сentre for Family Health and Human Reproduction Problems |
| record_format | Article |
| series | Acta Biomedica Scientifica |
| spelling | doaj.art-5a1b9dc062e24b2d9a6afb14cd15383c2025-01-27T16:48:53ZrusScientific Сentre for Family Health and Human Reproduction ProblemsActa Biomedica Scientifica2541-94202587-95962018-04-0132202410.29413/ABS.2018-3.2.3553Biomarkers for prediction and diagnostics of preeclampsiaO. V. Radkov0L. N. Korichkina1O. V. Sizova2Y. V. Volf3E. K. Paramonova4Tver State Medical UniversityTver State Medical UniversityTver State Medical UniversityE.M. Bakunina Regional Clinical Perinatal CentreE.M. Bakunina Regional Clinical Perinatal CentrePreeclampsia (PE) is a life-threatening complication of pregnancy associated with a high rate of maternal and perinatal morbidity and/or mortality. This study was aimed at evaluation of total and fetal cell-free DNA (cftDNA and cffDNA) in maternal plasma to assess whether this could represent a reliable predictive marker of early, late PE and whether intrauterine growth restriction (IUGR) as seen in PE is associated with levels of cell-free DNA. Diagnostic criteria for fetal growth retardation are calculated from the results of blood test results obtained in 26-36 weeks of gestation. We performed a PCR assay to compare the cftDNA and cffDNA concentration in maternal plasma among 3 groups of pregnant women. These included 119 women with overt PE (47 - early PE, 72 - late PE), 24 women at risk for the disease who developed PE (8 -early PE, 16 - late PE), and 30 controls. CffDNA quantification is a promising marker for early preeclampsia prediction. Cut-off value of 0,87 ng/ml for cffDNA (87.5 % sensitivity and 66,67 % specificity). Since the increase in cftDNA and cffDNA seems to be related to the presence IUGR in pregnancies which are complicated with early PE. Thus, it suggests that cftDNA and cffDNA could represent a potential biomarker of IUGR among individuals with early PE.https://www.actabiomedica.ru/jour/article/view/553preeclampsiafetal cell-free dnatotal cell-free dna |
| spellingShingle | O. V. Radkov L. N. Korichkina O. V. Sizova Y. V. Volf E. K. Paramonova Biomarkers for prediction and diagnostics of preeclampsia Acta Biomedica Scientifica preeclampsia fetal cell-free dna total cell-free dna |
| title | Biomarkers for prediction and diagnostics of preeclampsia |
| title_full | Biomarkers for prediction and diagnostics of preeclampsia |
| title_fullStr | Biomarkers for prediction and diagnostics of preeclampsia |
| title_full_unstemmed | Biomarkers for prediction and diagnostics of preeclampsia |
| title_short | Biomarkers for prediction and diagnostics of preeclampsia |
| title_sort | biomarkers for prediction and diagnostics of preeclampsia |
| topic | preeclampsia fetal cell-free dna total cell-free dna |
| url | https://www.actabiomedica.ru/jour/article/view/553 |
| work_keys_str_mv | AT ovradkov biomarkersforpredictionanddiagnosticsofpreeclampsia AT lnkorichkina biomarkersforpredictionanddiagnosticsofpreeclampsia AT ovsizova biomarkersforpredictionanddiagnosticsofpreeclampsia AT yvvolf biomarkersforpredictionanddiagnosticsofpreeclampsia AT ekparamonova biomarkersforpredictionanddiagnosticsofpreeclampsia |